Spain Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Description

List of Tables

GlobalData's "Spain Oncology Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Spain Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The Spain Oncology Market report provides key information and data on -

Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2024 company share data for Oncology Market.
Global corporate-level profiles of key companies operating within the Spain Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Spain Oncology is segmented as follows -

Colorectal Cancer Screening Tests
EGFR Tests
KRAS Tests
HER2 Tests
BRCA Tests
ALK Tests
BRAF Tests
BCR-ABL Tests
PD-L1 Tests

Reasons to Buy

The Spain Oncology Market report helps you to develop -

Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Product Code: GDME25624CCDB

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 What Is This Report About?
2.2 Oncology Market Segmentation
2.3 Definitions of Markets Covered in the Report

3 Oncology Market, Spain

3.1 Oncology Market, Spain, Revenue ($m), 2018-2033
- 3.1.1 ALK Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.2 BCR-ABL Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.3 BRAF Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.4 BRCA Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.5 Colorectal Cancer Screening Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.6 EGFR Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.7 HER2 Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
- 3.1.8 KRAS Tests Market, Spain, Revenue ($m), by Segment, 2018-2033
3.2 Oncology Market, Spain, Volume (Units), 2018-2033
- 3.2.1 ALK Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.2 BCR-ABL Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.3 BRAF Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.4 BRCA Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.5 Colorectal Cancer Screening Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.6 EGFR Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.7 HER2 Tests Market, Spain, Volume (Units), by Segment, 2018-2033
- 3.2.8 KRAS Tests Market, Spain, Volume (Units), by Segment, 2018-2033
3.3 Oncology Market, Spain, Average Price ($) , 2018-2033
3.4 Oncology Market, Spain, Company Share by Revenue ($m), 2024

4 Overview of Key Companies in Spain, Oncology Market

4.1 F. Hoffmann-La Roche Ltd
- 4.1.1 Company Overview
4.2 Agilent Technologies Inc
- 4.2.1 Company Overview
4.3 Qiagen NV
- 4.3.1 Company Overview
4.4 Abbott Laboratories
- 4.4.1 Company Overview
4.5 Danaher Corp
- 4.5.1 Company Overview
4.6 Resonac Corporation
- 4.6.1 Company Overview
4.7 Eiken Chemical Co Ltd
- 4.7.1 Company Overview
4.8 Alfresa Pharma Corp
- 4.8.1 Company Overview
4.9 BioGenex Laboratories Inc
- 4.9.1 Company Overview
4.10 Amoy Diagnostics Co Ltd
- 4.10.1 Company Overview

5 Oncology Market Pipeline Products

6 Financial Deals Landscape

6.1 Partnerships
- 6.1.1 A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix
6.2 Private Equity
- 6.2.1 Brookfield and Grifols Family May Acquire Grifols for USD5.95 Billion
6.3 Venture Financing
- 6.3.1 Universal Diagnostics SL (Universal DX) Secures Additional Series B Financing
- 6.3.2 The Blue Box Biomedical Solutions Secures USD0.54 Million in Venture Financing

7 Recent Developments

7.1 Corporate Communications
- 7.1.1 Jun 28, 2024: ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
7.2 Government and Public Interest
- 7.2.1 Jun 05, 2024: The 41st Barcelona Biomed Conference Reveals New Avenues For Cancer Prevention
7.3 Other Significant Developments
- 7.3.1 Mar 05, 2025: Atrys Chile and Interclinica Launch a New Telemedicine-Based Care Model to Reduce Stroke Response Time
- 7.3.2 Dec 20, 2024: Atrys Health Reduces Medical Care Times in Chile by 88% Thanks to Telemedicine and AI
7.4 Product News
- 7.4.1 Feb 06, 2025: Researchers Develop a Device That Replicates Tumours to Study the Efficacy of Immunotherapy Treatments
- 7.4.2 Nov 21, 2024: Researchers Identify Inflammatory Markers Related to the Prognosis of Breast Cancer
- 7.4.3 Nov 12, 2024: Researchers Identify a Potential Biomarker of Parkinson's Disease Progression
- 7.4.4 Oct 25, 2024: Scientists Identify Biomarkers in Semen Samples That Could Help Reduce Overdiagnosis in Prostate Cancer Screening
- 7.4.5 Jul 15, 2024: A New Biomarker Shows Potential to Evaluate Treatment Response for Metastatic Colorectal Cancer
- 7.4.6 Jul 15, 2024: Peptomyc S.L. Expands Patent Portfolio with European and Indian Patent Grant for its Methods and Composition for the Treatment of Cancer
- 7.4.7 Jul 12, 2024: A New Bioinformatics Algorithm Improves the Genetic Detection of Lynch and CMMRD Syndromes
- 7.4.8 Jul 09, 2024: Prostate Cancer Spreads by Sending Messages to Other Organs
- 7.4.9 Jul 04, 2024: A Genetic Test Will Improve the Diagnosis of a Rare Cancer Predisposition Syndrome in Children
- 7.4.10 Jul 01, 2024: Researchers Discover Biomarkers That Predict Response to Immunotherapy in Skin Carcinoma
- 7.4.11 Jun 04, 2024: VHIO Researchers Demonstrate the Utility of Ultrasensitive Liquid Biopsy to Predict and Monitor Response to Immunotherapy

8 Appendix

8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer

Product Code: GDME25624CCDB

List of Table

List of Tables

Table 1: Oncology Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 2: ALK Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 3: BCR-ABL Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 4: BRAF Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 5: BRCA Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 6: Colorectal Cancer Screening Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 7: EGFR Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 8: HER2 Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 9: KRAS Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 10: Oncology Market, Spain, Volume (Units), 2018-2033
Table 11: ALK Tests Market, Spain, Volume (Units), 2018-2033
Table 12: BCR-ABL Tests Market, Spain, Volume (Units), 2018-2033
Table 13: BRAF Tests Market, Spain, Volume (Units), 2018-2033
Table 14: BRCA Tests Market, Spain, Volume (Units), 2018-2033
Table 15: Colorectal Cancer Screening Tests Market, Spain, Volume (Units), 2018-2033
Table 16: EGFR Tests Market, Spain, Volume (Units), 2018-2033
Table 17: HER2 Tests Market, Spain, Volume (Units), 2018-2033
Table 18: KRAS Tests Market, Spain, Volume (Units), 2018-2033
Table 19: Oncology Market, Spain, Average Price ($), 2018-2033
Table 20: Oncology Market, Spain, Company Share by Revenue ($m), 2024
Table 21: Oncology Market Pipeline Products
Table 22: A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix
Table 23: Brookfield and Grifols Family May Acquire Grifols for USD5.95 Billion
Table 24: Universal Diagnostics SL (Universal DX) Secures Additional Series B Financing
Table 25: The Blue Box Biomedical Solutions Secures USD0.54 Million in Venture Financing
Table 26: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

List of Figure

List of Figures

Figure 1: Oncology Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 2: ALK Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 3: BCR-ABL Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 4: BRAF Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 5: BRCA Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 6: Colorectal Cancer Screening Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 7: EGFR Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 8: HER2 Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 9: KRAS Tests Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 10: Oncology Market, Spain, Volume (Units), 2018-2033
Figure 11: ALK Tests Market, Spain, Volume (Units), 2018-2033
Figure 12: BCR-ABL Tests Market, Spain, Volume (Units), 2018-2033
Figure 13: BRAF Tests Market, Spain, Volume (Units), 2018-2033
Figure 14: BRCA Tests Market, Spain, Volume (Units), 2018-2033
Figure 15: Colorectal Cancer Screening Tests Market, Spain, Volume (Units), 2018-2033
Figure 16: EGFR Tests Market, Spain, Volume (Units), 2018-2033
Figure 17: HER2 Tests Market, Spain, Volume (Units), 2018-2033
Figure 18: KRAS Tests Market, Spain, Volume (Units), 2018-2033
Figure 19: Oncology Market, Spain, Company Share (%), 2024